The Asco Post

Radiation oncology

Interventional Oncology and Its Role in the Management of Unresectable Hepatocellular CarcinomaJuly 25, 2014, Volume 5, Issue 12 - Supplement

Interventional therapies for hepatocellular carcinoma landed in interventional radiology’s wheelhouse a little over 20 years ago, with the development of doxorubicin-ethiodized oil emulsion and gelatin sponge particles to chemoembolize unresectable liver tumors.1,2 Median survival rates associate...

Read More

The Fourth Pillar of Oncology: Four Topics, Four Perspectives on the Role of Interventional Oncology in Managing Patients With Hepatocellular CarcinomaJuly 25, 2014, Volume 5, Issue 12 - Supplement

Interventional oncology has been called the fourth pillar of oncology—teaming up with medical oncology, surgical oncology, and radiation oncology disciplines in the fight against cancer. Recent data, reported in this supplement, suggest that interventional oncologic treatments for hepatocellular ...

Read More

SIR Names James B. Spies, MD, MPH, FSIR, as President, 2014–2015July 25, 2014, Volume 5, Issue 12 - Supplement

James B. Spies, MD, MPH, FSIR, Chair of the Radiology Department at MedStar Georgetown University Hospital and Professor of Radiology at Georgetown University Medical Center in Washington, D.C., assumed office as the Society of Interventional Radiology’s (SIR) 2014–2015 President during the Socie...

Read More

Impact of Bead Size on Response in Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial ChemoembolizationJuly 25, 2014, Volume 5, Issue 12 - Supplement

Almamoon Justaniah, MD, from the Department Radiology at Lahey Clinic in Burlington, Massachusetts, reported results from a study conducted at his institution to assess the influence of bead size on hepatocellular carcinoma response rate after drug-eluting bead transarterial chemoembolization.1 H...

Read More

In Patients With Unresectable Hepatocellular Carcinoma Receiving Transarterial Chemoembolization, Smaller Bead Size May Be Associated With More Liver-Related ComplicationsJuly 25, 2014, Volume 5, Issue 12 - Supplement

Data from a retrospective single-site study presented at the SIR 2014 Annual Scientific Meeting showed that utilization of 70- to 150-μm drug-eluting beads in transarterial chemoembolization for patients with unresectable hepatocellular carcinoma may cause greater liver-related complications than...

Read More

Drug-Eluting Bead Transarterial Chemoembolization Benefits Survival vs Supportive Care in Patients With Unresectable Hepatocellular CarcinomaJuly 25, 2014, Volume 5, Issue 12 - Supplement

Drug-eluting bead transarterial chemoembolization treatment for unresectable hepatocellular carcinoma yields significantly higher median overall survival rates than best supportive care in this patient population, according to a study by Minzhi Xing, MD, and Kevin Kim, MD, from the Division of In...

Read More

Bland vs Drug-Eluting Beads Show Similar Results for Embolization of Hepatocellular CarcinomaJuly 25, 2014, Volume 5, Issue 12 - Supplement

A single-blind controlled investigation found no difference in response or disease control rate at any time point between patients with unresectable hepatocellular carcinoma who had hepatic artery embolization performed with unloaded beads (in which no chemotherapeutic or other agent was added) v...

Read More

Chemoembolization Safe in Unresectable Hepatocellular Carcinoma Patients With Transjugular Intrahepatic Portosystemic ShuntJuly 25, 2014, Volume 5, Issue 12 - Supplement

Patients with unresectable hepatocellular carcinoma who also have a transjugular intrahepatic portosystemic shunt can receive doxorubicin-eluting bead chemoembolization safely and effectively, according to Michael Jordan Ray, MD, from the Department of Diagnostic Radiology at Baylor University Me...

Read More

Transarterial Chemoembolization Should Be Considered in Elderly Patients With Unresectable Hepatocellular CarcinomaJuly 25, 2014, Volume 5, Issue 12 - Supplement

Transarterial chemoembolization should be considered a reasonable locoregional therapeutic option in patients 65 or older with unresectable hepatocellular carcinoma, according to Niraj Bhalakia, MD, from the Department of Radiology at Thomas Jefferson University Hospital, Philadelphia. “In genera...

Read More

Phase II Study Finds Yttrium-90 Radioembolization Safe, Efficacious in Patients With Infiltrative Hepatocellular Carcinoma and Portal Vein ThrombosisJuly 25, 2014, Volume 5, Issue 12 - Supplement

Yttrium-90 radioembolization is a safe and efficacious therapy for patients with infiltrative hepatocellular carcinoma and portal vein thrombosis, according to research presented by Nima Kokabi, MD, from the Department of Interventional Radiology and Image Guided Medicine, Emory University School...

Read More

Yttrium-90 Radioembolization Improves Outcomes in Patients With Genotype 4 Hepatitis C and Hepatocellular Carcinoma, Study FindsJuly 25, 2014, Volume 5, Issue 12 - Supplement

Patients with unresectable hepatocellular carcinoma with portal vein tumor thrombosis and genotype 4 hepatitis C showed encouraging survival data after undergoing yttrium-90 radioembolization treatment, according to Mohamed H.K. Abdelmaksoud, MD, from the Department of Interventional Radiology at...

Read More

Simulation Shows Yttrium-90 Radioembolization Is Most Cost-Effective in Patients With Barcelona Clinic Liver Cancer Stage C Unresectable Hepatocellular CarcinomaJuly 25, 2014, Volume 5, Issue 12 - Supplement

Yttrium-90 radioembolization treatment is most cost-effective for hepatocellular cancer patients who present with Barcelona Clinic Liver Cancer stage C, according to data presented by Nassir Rostambeigi, MD, from the Department of Radiology at the University of Minnesota in Minneapolis. “The over...

Read More

Radiation Shielding Necessary for Physicians Delivering Yttrium-90 Radioembolization TreatmentJuly 25, 2014, Volume 5, Issue 12 - Supplement

Although radiation dose to health-care professionals delivering yttrium-90 radioembolization treatment is 1.4% that of fluoroscopy exposure, radiation shielding is necessary, according to Jong Yun Won, MD, from the Research Institute of Radiological Science, Yonsei University College of Medicine ...

Read More

Yttrium-90 Radioembolization Between  First- and Second-Line Chemotherapy May Improve Progression-Free Survival in Patients With Liver-Dominant Metastatic Colorectal CancerJuly 25, 2014, Volume 5, Issue 12 - Supplement

Preliminary data from a phase II trial indicate that ­yttrium-90 radioembolization, administered between first- and second-line chemotherapy for liver-dominant metastatic colorectal cancer, may improve progression-free survival, according to Kazim Narsinh, MD, from the Department of Radiology at ...

Read More

Three-Dimensional Magnetic Resonance Imaging May Deliver Better Colorectal Cancer Liver Metastases Assessment Response July 25, 2014, Volume 5, Issue 12 - Supplement

Three-dimensional (3D) magnetic resonance imaging (MRI) has the potential to refine the predictive value of tumor response assessment in patients with colorectal cancer metastases to the liver, reported Julius Chapiro, MD. Dr. Chapiro is with the Russell H. Morgan Department of Radiology and Radi...

Read More

Yttrium-90 Radioembolization Safe in Women With Metastatic Breast Cancer and Liver-Dominant DiseaseJuly 25, 2014, Volume 5, Issue 12 - Supplement

Radioembolization with yttrium-90 is safe in patients with metastatic breast cancer with liver-dominant disease late in their treatment course, and the treatment demonstrates consistent radiologic anti­tumoral response, according to data presented at the SIR 2014  Annual Scientific Meeting in San...

Read More

Yttrium-90 Radioembolization Shows Better Overall Survival vs Supportive Care in Patients With Unresectable Intrahepatic CholangiocarcinomaJuly 25, 2014, Volume 5, Issue 12 - Supplement

A retrospective population-based study demonstrated that patients with chemorefractory unresectable intrahepatic cholangiocarcinoma treated with yttrium-90 radioembolization had significantly greater median overall survival and favorable long-term survival rates compared with best supportive care...

Read More

Radioembolization and Issues in ReimbursementJuly 25, 2014, Volume 5, Issue 12 - Supplement

Edward Kim, MD, Director of Interventional Oncology and Assistant Professor of Radiology and Surgery in the Division of Vascular and Interventional Radiology at the Mount Sinai Medical Center in New York, headed a symposium held in conjunction with the SIR 2014 Annual Scientific Meeting. The symp...

Read More

FDA Approves Radioactive Diagnostic Imaging Agent to Help Determine the Extent of Head and Neck Cancer in the BodyJune 25, 2014, Volume 5, Issue 10

The U.S. Food and Drug Administration has approved a new use for technetium 99m tilmanocept (Lymphoseek Injection), a radioactive diagnostic imaging agent used to help doctors determine the extent to which squamous cell carcinoma has spread in the body’s head and neck region. In 2013, tilmanocept...

Read More

Georgetown Researchers Study Nonsurgical, Minimally Invasive Approach to Benign Prostatic HyperplasiaApril 15, 2014, Volume 5, Issue 6

Physicians at MedStar Georgetown University Hospital and Georgetown University Medical Center, Washington, DC, are studying the safety and effectiveness of prostate artery embolization in men with enlarged prostate glands and urinary obstruction. According to the National Institutes of Health, be...

Read More

American College of Radiology Issues Statement on Budgetary Efforts to Curtail Imaging and Radiation Oncology Self-ReferralApril 15, 2014, Volume 5, Issue 6

The American College of Radiology (ACR) recently issued a statement applauding steps to reign in medical imaging and radiation oncology self-referral included in the President’s fiscal year 2015 budget. However, prior authorization for imaging services, also included in the FY2015 budget, is unne...

Read More

Radiation Oncology Institute Awards $200,000 Grant to Christopher Slatore, MDFebruary 15, 2014, Volume 5, Issue 3

The Radiation Oncology Institute (ROI) has named Christopher G. Slatore, MD, recipient of a $200,000 award, distributed over 2 years, for a project to examine the comparative value of radiation therapy and patient outcomes among patients with lung cancer. Dr. Slatore is Assistant Professor in the...

Read More

NewYork-Presbyterian/Columbia University Medical Center Opens Irving Radiation Oncology CenterDecember 1, 2013, Volume 4, Issue 19

NewYork-Presbyterian/Columbia University Medical Center has opened its new Irving Radiation Oncology Center, part of the medical center’s Herbert Irving Comprehensive Cancer Center. The 12,500-square-foot facility provides precision radiation therapies and advanced diagnostic imaging for children...

Read More

Vertebral Compression Fracture Risk Increased After Spinal Stereotactic Body Radiotherapy November 15, 2013, Volume 4, Issue 18

In a study reported in Journal of Clinical Oncology, Arjun Sahgal, MD, of Princess Margaret Cancer Centre in Toronto, and colleagues evaluated the occurrence of vertebral compression fractures in patients undergoing spinal stereotactic body radiotherapy.1 Vertebral compression fractures occurred ...

Read More

ASTRO Offers Five Recommendations as Part of Choosing Wisely CampaignOctober 15, 2013, Volume 4, Issue 16

The American Society for Radiation Oncology (ASTRO) released its list of five radiation oncology-specific treatments that are commonly ordered but may not always be appropriate as part of the national Choosing Wisely® campaign, an initiative of the American Board of Internal Medicine Foundation. ...

Read More

SEER Analysis Shows Increased Survival with Surgery and Radiation Therapy in Metastatic Gastric Cancer July 10, 2013, Volume 4, Issue 11

A Surveillance, Epidemiology, and End Results (SEER) database analysis reported by Ravi Shridhar, MD, PhD, and colleagues in Cancer indicates that patients receiving surgery and radiation therapy for metastatic gastric cancer have prolonged survival compared with those receiving either alone or n...

Read More

Refractory Liver Metastases Yield to Yttrium-90 Radioembolization May 15, 2013, Volume 4, Issue 8

In patients with unresectable hepatic metastases from metastatic melanoma and neuroendocrine tumors, radioembolization led to good outcomes in studies from Emory University School of Medicine reported at the 38th Society of Interventional Radiology Annual Scientific Meeting, held recently in New ...

Read More

University of Michigan Launches New Cardio-oncology ProgramMay 15, 2013, Volume 4, Issue 8

The University of Michigan Samuel and Jean Frankel Cardiovascular Center, working with specialists at the University of Michigan (U-M) Comprehensive Cancer Center, has launched Michigan’s first cardio-oncology clinic, a program designed to prevent or minimize heart damage caused by chemotherapy a...

Read More

Elekta Receives FDA 510(k) Clearance Following Launch of New Versa HD Radiation Therapy System May 1, 2013, Volume 4, Issue 7

Elekta recently received 510(k) clearance from the FDA, allowing the company to begin shipping and installation of all components of the Versa HD system within the United States. The Versa HD radiation system, featuring high-precision beam shaping and tumor targeting, is capable of delivering rad...

Read More

Radiation, Still Misunderstood after All These Years April 15, 2013, Volume 4, Issue 6

Over the past few decades, radiation therapies have rapidly advanced, due, in large part, to an increasing technologic armamentarium. Among modern science’s most impressive machines, for example, 220-ton particle accelerators can generate near-light-speed beams of protons, with sniper-like precis...

Read More

On Radiation and Cancer RiskMarch 1, 2013, Volume 4, Issue 4

We owe our life to radiation. The universe was created in a thermonuclear explosion, and continued existence of life on Earth depends on plants using chlorophyll to capture light energy emitted by the sun (and exploding supernovas) and converting it into chemical energy, with the subsequent conve...

Read More

No Difference in Toxicity with Proton Radiotherapy vs Less Costly Intensity-modulated Radiotherapy February 1, 2013, Volume 4, Issue 2

A national sample of Medicare beneficiaries treated for prostate cancer with intensity-modulated radiation therapy or proton radiotherapy found that proton radiotherapy “was rare and expensive and associated with only a modest and transient reduction in genitourinary toxicity,” reported James B. ...

Read More

ASTRO Names Neurosurgeon Mark P. Carol, MD, 2012 Honorary MemberDecember 15, 2012, Volume 3, Issue 18

The American Society for Radiation Oncology (ASTRO) has named Mark P. Carol, MD, a distinguished leader in the fields of intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT), as its 2012 Honorary Member. The title of Honorary Member is the highest honor ASTRO bes...

Read More

Plenary Session Included Findings on Partial- vs Whole-breast Techniques and Patient Beliefs about RadiotherapyDecember 15, 2012, Volume 3, Issue 18

When the dates were picked for the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO), no one could have anticipated that the meeting would coincide with Hurricane Sandy’s devastation of parts of the northeast. As the storm approached on Monday and Boston shut down its tra...

Read More

Radiation Oncologists Are Discussing Infertility Risks with Young PatientsApri 15, 2012, Volume 3, Issue 6

More than 80% of radiation oncologists discuss the impact of cancer treatments on fertility with their patients of childbearing age. This can lead to improved quality of life for young patients with cancer, according to a study in Practical Radiation Oncology.1 In the past, the clinical focus fo...

Read More

Rising Costs in Radiation Oncology Linked to Medicare CoverageMarch 15, 2012, Volume 3, Issue 5

In the ongoing debate over how to control rising cancer care costs, it is vital to identify usage patterns of expensive new technologies. A recent study examined the relationship between Medicare reimbursement and the increasing use of intensity-modulated radiation therapy (IMRT).1 The ASCO Post ...

Read More

Fewer Rectal Side Effects with IMRT than with 3D-CRT for Prostate CancerNovember 15, 2011, Volume 2, Issue 17

The use of intensity-modulated radiation therapy (IMRT) is associated with fewer acute and late toxic effects than is three-dimensional conformal radiation therapy (3D-CRT) in men with localized prostate cancer, according to preliminary analysis of the Radiation Therapy Oncology Group (RTOG) 0126...

Read More

Preoperative Chemoradiotherapy May Extend Survival for Patients with Esophagogastric Junction AdenocarcinomaNovember 15, 2011, Volume 2, Issue 17

Several American and European clinical trials have yielded mixed results on the survival advantage of preoperative chemoradiotherapy for patients with locally advanced esophagogastric junction adenonocarcinoma. However, a distinguished panel at the 2011 ASTRO Annual Meeting did agree that surgery...

Read More

Despite Challenges, Combined-modality Therapy Warranted for Locally Recurrent Colorectal CancerNovember 15, 2011, Volume 2, Issue 17

Encouraging outcomes have been achieved with a combined-modality treatment approach for patients with locally recurrent colorectal cancer in both curative and palliative settings, although room for improvement remains. During a session presented at the American Society for Radiation Oncology (AST...

Read More

Hypofractionated Radiotherapy Effectively Controls High-risk Prostate CancerNovember 15, 2011, Volume 2, Issue 17

The use of hypofractionated intensity-modulated radiotherapy (IMRT) appears to be a reasonable option for men with intermediate- to high-risk prostate cancer,1 reported Alan Pollack, MD, Chairman of Radiation Oncology at the University of Miami Miller School of Medicine in Miami and lead investig...

Read More
More on Twitter